drugset / Trial / NCT00626288

Mesalazine Therapy in Patients With Irritable Bowel Syndrome

NCT00626288

Phase 3 Completed 187 enrolled SOFAR S.p.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether Mesalazine is effective in the treatment of the abdominal discomfort or pain of Irritable Bowel Syndrome patients.

Timeline

Start
2007-12
Primary completion
2012-03
Completion
2012-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 800 mg